Go Pro
ETR:SAZ

STADA Arzneimittel Aktiengesellschaft (SAZ) Stock Price, News & Analysis

STADA Arzneimittel Aktiengesellschaft logo
€80.40 0.00 (0.00%)
As of 11/27/2018

About STADA Arzneimittel Aktiengesellschaft Stock (ETR:SAZ)

Key Stats

Today's Range
€79.56
€80.98
50-Day Range
€80.40
€80.40
52-Week Range
€53.41
€80.98
Volume
92,068 shs
Average Volume
51,761 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

Receive SAZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SAZ Stock News Headlines

Get my No. 1 gold stock now
Gold has broken past 4400 per ounce, and major banks think it has further to run. Goldman Sachs now sees 4900, while JPMorgan projects 6000 by year-end. Some analysts point to a broader monetary shift, dubbed the Mar-a-Lago Accord, as a driving force behind the rally. Hedge fund investors, including Steven Cohen, are reportedly building positions.tc pixel
Arzneihersteller Stada hat Russland-Geschäft abgespalten
See More Headlines

SAZ Stock Analysis - Frequently Asked Questions

STADA Arzneimittel Aktiengesellschaft's stock was trading at €80.40 on January 1st, 2026. Since then, SAZ stock has increased by 0.0% and is now trading at €80.40.

Based on aggregate information from My MarketBeat watchlists, some other companies that STADA Arzneimittel Aktiengesellschaft investors own include ProSiebenSat.1 Media (PSM), Renault (RNO), Volkswagen (VOW3), Andersons (ANDE), Nuwellis (CHFS) and Chemed (CHE).

Industry, Sector and Symbol

Stock Exchange
ETR
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
ETR:SAZ
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (ETR:SAZ) was last updated on 8/18/2026 by MarketBeat.com Staff.
From Our Partners